TrialThe Lancet. Oncology2015

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Farhad Ravandi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.